Literature DB >> 10930356

Comparison of urinary desmosine excretion in patients with chronic obstructive pulmonary disease or cystic fibrosis.

D C Bode1, E D Pagani, W R Cumiskey, R von Roemeling, L Hamel, P J Silver.   

Abstract

Neutrophil elastase is involved in the pathogenesis of several pulmonary diseases; a strategy for monitoring in vivo elastase activity is to measure changes in biochemical markers. The objective of this study was to determine whether differences in the urinary excretion of the elastin crosslinks, desmosine and isodesmosine (which are unique amino acid products of elastase activity), could be discerned between groups of patients with chronic obstructive pulmonary disease (COPD) or cystic fibrosis (CF), and non-diseased, age-matched controls. Twenty-four-hour urine collections were analysed to eliminate variations in excretion throughout the day, and urine was collected on four separate days in 29-31 subjects/group to investigate the variability in desmosines excretion among the groups. Both sets of patient populations had significantly more variable desmosines readings (higher standard deviations) relative to their respective age-matched control group. The means for three adult groups (COPD, controls and a COPD-smoker subset) ranged from 28.4 to 35.5 pmol desmosines/mg creatinine and there were no differences among the groups. Values in children were higher: 55 pmol desmosines/mg creatinine in the non-CF children and 77 pmol desmosines/mg creatinine for the CF group (P<0.01 vs. age-matched controls). The results of this study show that urinary desmosines, as a surrogate marker for enhanced elastase activity, are more highly variant in both patient populations relative to age-matched controls, and an overall increase in the mean value is further observed in patients with cystic fibrosis. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10930356     DOI: 10.1006/pupt.2000.0245

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  6 in total

1.  Sputum desmosine during hospital admission for pulmonary exacerbation in cystic fibrosis.

Authors:  Theresa A Laguna; Brandie D Wagner; Heidi K Luckey; Shelley A Mann; Scott D Sagel; Warren Regelmann; Frank J Accurso
Journal:  Chest       Date:  2009-06-30       Impact factor: 9.410

2.  Quantification of desmosine and isodesmosine using MALDI-ion trap tandem mass spectrometry.

Authors:  Pratikkumar Rathod; Manjeet Kaur; Hsin-Pin Ho; Marissa E Louis; Basant Dhital; Philip Durlik; Gregory S Boutis; Kevin J Mark; Jong I Lee; Emmanuel J Chang
Journal:  Anal Bioanal Chem       Date:  2018-07-31       Impact factor: 4.142

3.  Urinary desmosine: a biomarker of structural lung injury during CF pulmonary exacerbation.

Authors:  Theresa A Laguna; Brandie D Wagner; Barry Starcher; Heidi K Luckey Tarro; Shelley A Mann; Scott D Sagel; Frank J Accurso
Journal:  Pediatr Pulmonol       Date:  2012-03-19

4.  The applicability of urinary creatinine as a method of specimen normalization in the cystic fibrosis population.

Authors:  Brandie D Wagner; Frank J Accurso; Theresa A Laguna
Journal:  J Cyst Fibros       Date:  2010-03-15       Impact factor: 5.482

5.  Higher urine desmosine levels are associated with mortality in patients with acute lung injury.

Authors:  Dana E McClintock; Barry Starcher; Mark D Eisner; B Taylor Thompson; Doug L Hayden; Gwynne D Church; Michael A Matthay
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-05-12       Impact factor: 5.464

6.  High-sensitivity nanoLC-MS/MS analysis of urinary desmosine and isodesmosine.

Authors:  Michel Boutin; Carl Berthelette; François G Gervais; Mary-Beth Scholand; John Hoidal; Mark F Leppert; Kevin P Bateman; Pierre Thibault
Journal:  Anal Chem       Date:  2009-03-01       Impact factor: 6.986

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.